Valneva (NASDAQ:VALN) Shares Gap Up – What’s Next?

Valneva SE Sponsored ADR (NASDAQ:VALN) gapped up before the market opened on Wednesday . The stock had previously closed at $11.01, but opened at $11.46. Valneva shares last traded at $11.11, with a volume of 4,380 shares changing hands.

Wall Street Analyst Weigh In

Separately, Wall Street Zen lowered Valneva from a “hold” rating to a “sell” rating in a research report on Saturday, December 6th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $15.00.

Valneva Trading Down 6.3%

The company has a quick ratio of 1.36, a current ratio of 2.38 and a debt-to-equity ratio of 1.52. The company has a market capitalization of $903.29 million, a P/E ratio of -6.64 and a beta of 1.80. The firm’s 50-day moving average price is $10.28 and its 200 day moving average price is $9.67.

Institutional Trading of Valneva

Several institutional investors and hedge funds have recently modified their holdings of VALN. XTX Topco Ltd bought a new position in shares of Valneva in the fourth quarter valued at approximately $94,000. China Universal Asset Management Co. Ltd. bought a new stake in Valneva during the fourth quarter worth $44,000. JPMorgan Chase & Co. bought a new stake in Valneva during the third quarter worth $124,000. VSM Wealth Advisory LLC raised its position in Valneva by 125.0% in the 3rd quarter. VSM Wealth Advisory LLC now owns 9,000 shares of the company’s stock valued at $110,000 after buying an additional 5,000 shares during the last quarter. Finally, Marex Group plc bought a new position in Valneva during the 2nd quarter valued at $64,000. 11.39% of the stock is owned by hedge funds and other institutional investors.

Valneva Company Profile

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.